Sellas Life Sciences Groupincis A Late Stage Clinical Biopharmaceutical Company Based In New York Citydedicated To Developing Innovative Therapies For Various Cancer Indicationsfounded In 2012The Company Focuses On Advancing Precision Medicine Through Immunotherapy And Targeted Cancer Therapiesparticularly For Aggressive Hematologic Malignancies And Solid Tumors Sellas Has Two Main Candidates In Its Therapeutic Pipelinegalinpepimut Sgpsis A Peptide Immunotherapy Targeting The Wilms Tumor 1Wt1Proteincurrently In Late Stage Clinical Trials For Hematologic Malignancies And Solid Tumorssls009 Is A Selective Cdk9 Inhibitor In Phase 1 Trialsaimed At Treating Relapsed Refractory Acute Myeloid Leukemia And Other Hematologic Cancersthe Company Emphasizes Biomarker Driven Approaches To Optimize Patient Outcomes And Collaborates With Clinical Trial Networks To Identify Eligible Patients Under The Leadership Of Drangelos Mstergiousellas Aims To Bridge Scientific Innovation With Clinical Executionenhancing Treatment Options For Oncology Patients With Limited Alternatives
